Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atrial Fibrillation
Dr. Andrea Natale files IDE for use of the linear ablation technology
July 24th, 2005
Cardima, Inc., (CRDM) announced that Dr. Andrea Natale, medical director for the Center for Atrial Fibrillation, director of the Electrophysiology Laboratories, and co-section head of pacing and electrophysiology in the Cleveland Clinic department of cardiovascular medicine, has filed an investigational device exemption (IDE) with the U.S. Food and Drug Administration (FDA) to use the Cardima, Inc.'s, linear ablation technology to create continuous linear lesions in the left atrium of the heart for the treatment of chronic atrial fibrillation (AF). The IDE includes the use of REVELATION T-Flex microcatheter and the INTELLITEMP Energy Management System. The REVELATION...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
